Enveric regains Nasdaq minimum bid price compliance; delisting risk removed

Enveric Biosciences, Inc.

Received Nasdaq letter on Nov 12, 2025 confirming compliance with Listing Rule 5550(a)(2).
Minimum bid price deficiency now considered closed by Nasdaq.
No further action required; company remains listed on Nasdaq Capital Market.

item 8.01

Enveric Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-023444

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.